- Report
- September 2026
- 194 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,076GBP
- Report
- September 2026
- 269 Pages
Global
From €5316EUR$5,850USD£4,569GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,506GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,506GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,506GBP
- Report
- July 2026
- 200 Pages
Global
From €7260EUR$7,990USD£6,240GBP
- Report
- December 2025
- 200 Pages
Global
From €7224EUR$7,950USD£6,209GBP
- Report
- November 2025
- 200 Pages
Global
From €7224EUR$7,950USD£6,209GBP
- Report
- April 2026
- 148 Pages
Global
From €2725EUR$2,999USD£2,342GBP
€3634EUR$3,999USD£3,123GBP
- Report
- August 2026
- 120 Pages
Global
From €4316EUR$4,750USD£3,710GBP
- Report
- November 2025
- 150 Pages
Global
From €4407EUR$4,850USD£3,788GBP
- Report
- October 2025
- 150 Pages
Global
From €4407EUR$4,850USD£3,788GBP
- Report
- October 2024
- 100 Pages
Global
From €5406EUR$5,950USD£4,647GBP
- Report
- August 2025
- 191 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,076GBP
- Report
- May 2024
- 132 Pages
Global
From €2725EUR$2,999USD£2,342GBP
€3634EUR$3,999USD£3,123GBP
- Report
- October 2024
- 200 Pages
Global
From €3407EUR$3,750USD£2,929GBP
- Report
- August 2022
- 115 Pages
Global
From €4089EUR$4,500USD£3,514GBP
- Report
- August 2022
- 102 Pages
Global
From €4089EUR$4,500USD£3,514GBP
- Report
- April 2025
- 200 Pages
Global
From €7224EUR$7,950USD£6,209GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2534EUR$2,789USD£2,178GBP

Linaclotide is a medication used to treat chronic constipation and irritable bowel syndrome with constipation (IBS-C). It is a guanylate cyclase-C agonist, which works by increasing the secretion of chloride and bicarbonate into the intestine, resulting in increased intestinal fluid and improved bowel movements. It is available in the form of capsules and is taken orally once a day.
Linaclotide is a relatively new drug in the gastrointestinal market, having been approved by the US Food and Drug Administration (FDA) in 2012. It is the only guanylate cyclase-C agonist approved for the treatment of IBS-C and chronic constipation. It has been shown to be effective in relieving symptoms of constipation and IBS-C, and is generally well-tolerated.
The linaclotide market is highly competitive, with several companies offering their own versions of the drug. These include Ironwood Pharmaceuticals, Allergan, AstraZeneca, and Shire. Show Less Read more